ero12 Antibody

What is the Estrogen Receptor Ab-12 antibody and what are its key specifications?

The Estrogen Receptor Ab-12 (clone 6F11) is a mouse monoclonal antibody that specifically targets the estrogen receptor protein. It was developed using recombinant full-length estrogen receptor protein as the immunogen and belongs to the IgG1 isotype. This antibody recognizes the estrogen receptor, which has a molecular weight of approximately 67 kDa and is primarily localized in the nucleus .

Why is the estrogen receptor important in cellular and cancer biology?

The estrogen receptor (ER) serves as a crucial regulator of growth and differentiation in the mammary gland. Its presence in breast tumors has significant clinical implications, as it indicates an increased likelihood of response to anti-estrogen therapies such as tamoxifen . The ER gene consists of more than 140kb of genomic DNA divided into 8 exons and translates into a protein with six functionally discrete domains, which are required for transcription activation function, binding to estrogen response elements (ERE), constitutive dimerization, binding to heat shock proteins, and ligand recognition .

How does ER Ab-12 differ from other antibody types used in research?

Unlike polyclonal or recombinant antibodies, ER Ab-12 is a monoclonal antibody, meaning it is derived from a single B-cell clone and recognizes a specific epitope on the estrogen receptor protein. This confers high specificity and consistency across experimental batches. While various antibody formats exist for research applications, monoclonal antibodies like ER Ab-12 offer particular advantages in reproducibility and specificity when working with complex samples .

What are the validated applications for ER Ab-12 in research settings?

The ER Ab-12 antibody has been validated for several key research applications, allowing for comprehensive study of estrogen receptor expression and function:

Researchers should follow established protocols for each application while incorporating appropriate positive controls (MCF-7 cells or breast carcinoma tissue) to ensure reliable results .

What is the optimal protocol for immunohistochemistry using ER Ab-12?

For optimal immunohistochemical detection of estrogen receptor using ER Ab-12, researchers should follow this general protocol:

• Prepare formalin-fixed, paraffin-embedded tissue sections (4-6 μm thickness)

• Perform deparaffinization and rehydration through xylene and graded alcohols

• Conduct heat-induced epitope retrieval (typically using citrate buffer pH 6.0)

• Block endogenous peroxidase activity (3% H₂O₂) and non-specific binding sites

• Apply optimized dilution of ER Ab-12 (specific dilution should be determined empirically)

• Incubate at appropriate temperature and duration (typically 4°C overnight or 1-2 hours at room temperature)

• Apply detection system compatible with mouse primary antibodies

• Counterstain, dehydrate, and mount

MCF-7 cells or known ER-positive breast carcinoma should be included as positive controls, while negative controls should involve omission of primary antibody .

How should Western blotting be performed with ER Ab-12 for reliable results?

For Western blotting applications using ER Ab-12, researchers should follow these methodological steps:

• Prepare protein lysates under denaturing conditions with appropriate protease inhibitors

• Separate proteins (20-50 μg per lane) by SDS-PAGE (8-10% gel recommended)

• Transfer proteins to PVDF or nitrocellulose membrane

• Block non-specific binding sites (typically 5% non-fat dry milk or BSA)

• Incubate with optimized dilution of ER Ab-12

• Wash thoroughly to remove unbound antibody

• Apply HRP-conjugated secondary antibody specific to mouse IgG

• Develop using chemiluminescent substrate

• Verify detection of 67 kDa band corresponding to estrogen receptor

MCF-7 cell lysate should be included as a positive control. Optimization of antibody concentration and incubation conditions may be necessary for different sample types .

How can ER Ab-12 be used to investigate hormone-responsive cancer mechanisms?

ER Ab-12 serves as a valuable tool for investigating the molecular mechanisms underlying hormone-responsive cancers, particularly breast cancer. Researchers can use this antibody to:

• Characterize ER expression patterns in different tumor subtypes

• Correlate ER status with clinical outcomes and treatment response

• Investigate changes in ER localization following hormone treatment

• Study interactions between ER and co-regulatory proteins through co-immunoprecipitation

• Examine ER recruitment to specific genomic loci using chromatin immunoprecipitation

The presence of ER in breast tumors, detectable using ER Ab-12, indicates an increased likelihood of response to anti-estrogen therapy, making this antibody particularly valuable for translational research connecting basic science with clinical applications .

What considerations are important when using ER Ab-12 for multiplex immunofluorescence studies?

When designing multiplex immunofluorescence experiments involving ER Ab-12:

• Primary antibody compatibility: Ensure other primary antibodies are raised in different host species to avoid cross-reactivity

• Fluorophore selection: Choose fluorophores with minimal spectral overlap

• Sequential staining: Consider sequential rather than simultaneous application of antibodies

• Blocking optimization: Implement thorough blocking steps between antibody applications

• Control samples: Include single-stained controls for establishing spectral unmixing parameters

These methodological considerations help ensure reliable detection of estrogen receptor alongside other targets of interest in complex tissue samples, enabling comprehensive analysis of hormone receptor signaling networks in research contexts.

How does antibody validation methodology differ between basic and advanced applications of ER Ab-12?

Advanced applications require more rigorous validation approaches to ensure specificity and reliability, particularly when examining complex signaling networks or when results will inform therapeutic decision-making .

What are the most common technical challenges when using ER Ab-12 and how can they be addressed?

Systematic optimization and inclusion of appropriate controls can help resolve most technical challenges encountered with ER Ab-12 applications .

How can researchers distinguish between specific and non-specific binding when using ER Ab-12?

To ensure that observed signals represent specific binding of ER Ab-12 to the estrogen receptor rather than non-specific interactions, researchers should implement these critical validation steps:

• Include known positive controls (MCF-7 cells, breast CA) and negative controls (ER-negative cell lines)

• Perform isotype control experiments using non-specific mouse IgG1 at the same concentration

• Verify nuclear localization pattern consistent with known ER biology

• Correlate immunohistochemical findings with orthogonal techniques (e.g., RT-PCR for ER transcript)

• Compare staining patterns with other validated ER antibodies targeting different epitopes

What quality control measures should be implemented when working with ER Ab-12 across multiple experiments?

To maintain experimental consistency when using ER Ab-12 across multiple studies or timepoints:

• Aliquot antibody upon receipt to minimize freeze-thaw cycles

• Include standard positive controls (MCF-7 cells) in each experimental run

• Maintain consistent antibody dilutions and incubation conditions

• Document lot numbers and maintain detailed experimental protocols

• Perform periodic validation of antibody performance using established control samples

• Consider preparing a laboratory reference standard for long-term projects

These quality control measures help ensure reproducibility and reliability of data generated using ER Ab-12, particularly for longitudinal studies or collaborative research projects .

How does the methodology for ER Ab-12 compare to antibodies targeting other hormone receptors?

While ER Ab-12 specifically targets the estrogen receptor, researchers often need to examine multiple hormone receptors in parallel. The methodological approaches for ER Ab-12 share similarities with those for other receptor antibodies, but important differences exist:

Understanding these comparative aspects helps researchers design comprehensive studies of hormone receptor networks in various physiological and pathological contexts .

What methodological adaptations are needed when switching between monoclonal antibodies like ER Ab-12 and other antibody formats?

When transitioning between different antibody formats for estrogen receptor detection, researchers should consider these methodological adaptations:

These format-specific considerations help ensure optimal results when comparing data across studies using different antibody types .

How can ER Ab-12 be effectively used in conjunction with single-cell analysis technologies?

The integration of ER Ab-12 with emerging single-cell methodologies offers powerful approaches for understanding estrogen receptor biology at unprecedented resolution:

• Single-cell immunofluorescence: ER Ab-12 can be used in multiparameter imaging to correlate ER expression with other markers at the single-cell level

• Mass cytometry (CyTOF): When conjugated to metal isotopes, ER Ab-12 can be incorporated into high-dimensional single-cell phenotyping panels

• Imaging mass cytometry: Enables spatial analysis of ER expression in tissue context with subcellular resolution

• Single-cell Western blotting: Allows quantification of ER protein levels in individual cells

These integrated approaches require careful optimization of ER Ab-12 concentration, conjugation protocols, and validation with appropriate controls to ensure specificity at the single-cell level .

What considerations are important when applying ER Ab-12 in high-throughput screening applications?

For high-throughput applications involving ER Ab-12, researchers should address these methodological considerations:

• Assay miniaturization: Optimize antibody concentration for reduced volumes while maintaining sensitivity

• Automation compatibility: Ensure protocols are adaptable to automated liquid handling systems

• Detection methods: Select high-sensitivity detection systems compatible with microplate formats

• Standardization: Implement robust positive and negative controls on each plate

• Data normalization: Develop appropriate normalization strategies to account for plate-to-plate variation

These adaptations enable reliable use of ER Ab-12 in screening applications, such as evaluating estrogen receptor modulators or analyzing receptor expression across large sample collections .